Pickering stabilized nanocellulose-alginate: A diosgenin-mediated delivery of quinalizarin as a potent cyto-inhibitor in human lung/breast cancer cell lines

Publication date: April 2020Source: Materials Science and Engineering: C, Volume 109Author(s): Sevinc Ilkar Erdagi, Fahanwi Asabuwa Ngwabebhoh, Ufuk YildizAbstractThe current study explores the facile fabrication of multilayer self-assembled electrostatic oil-in-water Pickering emulsions (PEs) using quaternized nanocellulose (Q-NC) and diosgenin-conjugate alginate (DGN-ALG) particles as stabilizers to form hydrocolloid nanocarriers. The conditions of formulation such as storage time, pH, temperature and salt effect on the emulsion stability were evaluated. The results deduced showed good emulsion droplet stability over a period of 30 days. Morphological analysis revealed the hydrodynamic sizes of the PE droplets to be spherically shaped with an average diameter of 150 ± 3.51 nm. Creaming index, wettability and critical aggregation concentrations (CAC) as well as chemical characterization of the PEs were examined. In vitro release kinetics of encapsulated quinalizarin as a model drug was investigated with a determined cumulative drug release (CDR) of 89 ± 1.21% in simulated pH blood medium of pH 7.4. In addition, cellular internalization of the PEs was studied via confocal microscopy imaging and showed high cellular uptake. Also, evaluated in vitro cytotoxicity by MTT assay demonstrated excellent anticancer activity in human lung (A549) and breast (MCF-7) cancer cell lines.Graphical abstract
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research

Related Links:

CONCLUSION: PSs represent a potential tool to treat this form of breast cancer by providing peptides that may be useful in therapy. PMID: 32065785 [PubMed - in process]
Source: Breast Disease - Category: Cancer & Oncology Tags: Breast Dis Source Type: research
Condition:   Survival, Prosthesis Intervention:   Diagnostic Test: Osteopontin Sponsor:   Mansoura University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Breast Cancer Intervention:   Drug: [18F]-FDG Sponsor:   University of Alabama at Birmingham Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer Female;   BRCA1 Mutation;   BRCA2 Mutation Intervention:   Other: liquid biopsy Sponsors:   Centre Jean Perrin;   International Cancer Research Group;   Institut Max Planck d'optique quantique Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Intervention:   Procedure: Sentinel lymph node biopsy Sponsor:   Bulent Ecevit University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Cancer Interventions:   Drug: Venetoclax;   Drug: Capecitabine Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we encapsulated the Ver and Dox in PLGA nanoparticles to inhibit the P-gp drug efflux in breast cancer. Moreover, the effect of either Dox solution (DoxS), Dox nanoparticles (DoxNP), DoxS+ VerS, DoxNP+VerS, DoxNP + VerNP or Dox-VerNP was evaluated. It was found that co administration of DoxNP with VerNP (70.76%) showed similar cellular uptake of Dox to Dox/Ver combination solution (70.62%). However it is observed that DoxNP+ VerNP has the highest apoptotic activity (early apoptotic 13.52±0.06%, late apoptotic 53.94±0.15%) on human breast adenocarcinoma (MCF 7) cells. Hence, it is suggested that...
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
The objective of our study was to assess the co-prescription of CYP2D6 inhibitors and tamoxifen use and also to relate concomitant CYP2D6 inhibitor use and tamoxifen adherence to breast cancer in Riyadh, Saudi Arabia. All patients treated for breast cancer who had at least one tamoxifen prescription in their electronic medical records (EMRs) from June 2015 to June 2017 were included. Patients who had other adjuvant hormonal therapy were excluded from the study. In total, 499 patients (25 males and 474 females) with breast cancer using tamoxifen were included. Our study was purely observational study revealed...
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
The first pilot study of robot-assisted high-precision supermicrosurgery in humans shows it is safe for treating breast cancer-related lymphedema.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
If you’ve been following me on social media, you might have noticed some posts with the hashtag #TMFchessjourney. These document my ongoing mission to practice chess at a professional level, what I’ve learnt from it and how it helps me grow as a person. Recently, I’ve crossed the 1000 hour bar of chess time and it has been a truly humbling experience. From finally learning the art of patience to getting bested by pre-teens to inching closer to the language of A.I., I was in for quite the ride and this is merely the beginning! I’m thrilled to take you on this Chess Journey today,  so strap up...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Artificial Intelligence AI chess Source Type: blogs
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Materials Science | Nanotechnology | Science | Sodium Chloride | Study